We recently demonstrated that endothelin-1 (ET-1) was strongly expressed in inflamed gingival tissues, but the biological role of ET-1 in gingival tissue remains unknown. This study focused on the relationship between ET-1 and interleukin-1β (IL-1β), an important cytokine during the periodontal inflammatory process. We determined the protein levels of ET-1 and IL-1β in gingival tissues from patients and examined whether ET-1 could regulate the expression of the IL-1β gene and protein in oral epithelial cells and fibroblasts in vitro. There was a significant correlation between the levels of ET-1 and IL-1β in 26 gingival tissues, as determined by ELISA. Following the confirmation of two specific ET-1 receptors (ET A and ET B receptors) on the cultured cells, the effects of ET-1 stimulation on IL-1β mRNA and protein expression were evaluated by RT-PCR and ELISA, respectively. The IL-1β mRNA and protein levels were enhanced by ET-1 stimulation in a dose-dependent manner, and the enhancement of IL-1β was inhibited by ET A or ET B receptor antagonists. These findings indicate that ET-1 is involved in the regulation of IL-1β expression in gingival tissues and suggest that ET-1 signaling to the cells may be a therapeutic target for treating IL-1β-dependent inflammatory responses.
Periodontitis is an inflammatory disease with an as yet unclear aetiology (6) and results in the destruction of the supporting osseous and connective tissues of the teeth (8, 12) . During the initiation and progression of periodontal disease, inflammatory cytokines are considered to be important modulators of inflammation (2, 27) . Interleukin-1 (IL-1), a proinflammatory cytokine, plays a central role in immune regulation and a variety of inflammatory responses; it has been identified as a periodontal disease marker due to its function as not only an inflammatory mediator but also a modulator of extracellular matrix and bone (4, 9) . Thus, the synthesis, secretion, and biological activity of IL-1 cytokines have been identified as therapeutic targets for inflammatory disorders such as periodontitis (20) . Endothelin (ET)-1, a 21-amino-acid peptide, was originally isolated from the culture supernatant of porcine aortic endothelial cells. ET-1 has multiple biological actions and is produced by a variety of tissues and cells (25, 35) . The effects of ET-1 are mediated through binding to endothelin A (ET A ) and endothelin B (ET B ) G-protein-coupled receptors expressed on the cell surface of various cells. ET-1 has been implicated in the pathogenesis of many diseases, including hypertension, atherosclerosis, and cardiovascular disease (1, 5, 10, 25, 29) . Previous studies have reported that the ET-1 expression and release are induced during inflammatory processes such as gastric mucosal inflammation, rhini-200 mM L-glutamine, 10% FBS, 100 units/mL penicillin and 100 μg/mL streptomycin (GIBCO, Renfrewshire, UK), under an atmosphere containing 5% CO 2 at 37°C. To study the release of IL-1β from both HPdLF and KB cells, cells were seeded into six-well tissue culture plates (Iwaki, Asahi Glass Co., Ltd., Tokyo, Japan), at 1 × 10 5 cells per well. On the next day, the HPdLF and KB cells were washed once with PBS and then incubated for 24 h in serum-free SCBM and serum-free DMEM, respectively. The cells were incubated for a further 24 h in the respective medium supplemented with increasing concentrations (1 nM, 10 nM, and 100 nM) of human ET-1 (Peptide Institute, Osaka, Japan), or 100 nM ET-1 and 100 nM of the specific ET A receptor antagonist BQ123 (Alexis Biochemicals, Nottingham, UK), or 100 nM ET-1 and 100 nM of the specific ET B receptor antagonist BQ788 (Alexis Biochemicals). When BQ123 and BQ788 were used, the cells were pre-incubated with the antagonists for 20 min before ET-1 treatment. To evaluate IL-1β mRNA expression in HPdLF and KB cells, the cells were incubated for a further 12 h following treatment with ET-1 and its antagonists. The post-ET-1 treatment incubation times that were optimal for investigating the expression of IL-1β mRNA and protein were determined in preliminary experiments. After incubation, the cell supernatants were harvested, clarified by centrifugation, and stored at −80°C until use.
Immunoblotting. The KB, NHDF, and HPdLF cells were grown to near confluence in six-well culture plates and lysed with lysis buffer composed of 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton-X100, and protease inhibitors. Lysate samples were fractionated by 12% SDS-PAGE and transferred to PVDF membranes (Hybond-P; GE Healthcare, Buckinghamshire, UK). The membranes were probed with anti-ET A receptor polyclonal antibody (pAb) (diluted 1 : 350; Alexis Biochemicals, San Diego, CA, USA), anti-ET B receptor pAb (1 : 500; Alexis Biochemicals), or anti-β-actin pAb (1 : 1,000; Stressgen Bioreagents Corp., Victoria, Canada), followed by incubation with horseradish-peroxidase (HRP)-conjugated anti-sheep IgG (1 : 3,000; American Qualex, San Clemente CA, USA), or HRP-conjugated anti-rabbit IgG (1 : 5,000; Bio-Rad, Richmond, CA, USA) as a secondary antibody. After additional washes, bound antibodies were detected using ECL reagents (GE Healthcare).
tis, and asthmatic inflammation, and that ET-1 interacts with pro-inflammatory cytokines such as IL-1β in inflammatory processes (17, 31, 32) . Recently, we showed that ET-1 was strongly expressed in gingival epithelial and endothelial cells of inflamed gingival tissue (33) and that infection by Porphyromonas gingivalis, a pathogenic bacterium in periodontitis, up-regulated the expression of ET-1, along with IL-1β, IL-8, and intercellular adhesion molecule 1 (ICAM-1), in bronchial epithelial cells (3) . Thus, ET-1 is possibly related to the inflammatory pathogenesis of periodontitis and other diseases, and may be involved in the regulation of cytokines. Nevertheless, little is known about the pathophysiological role of ET-1 in periodontitis.
In this study, we focused on the relationship between ET-1 and IL-1β, an important cytokine in the inflammatory process of periodontitis, and sought to verify whether ET-1 expressed in inflamed gingival tissue could regulate IL-1β production in epithelial cells and fibroblasts from gingival tissue.
MATERIALS AND METHODS
Tissue specimens. In total, 26 gingival tissue samples for examination were obtained from 21 adult patients (9 males, 12 females; mean age ± SD, 30.3 ± 9.2 years) who were attending the hospital at Kyushu Dental College for periodontal treatment or maintenance. All patients were classified as having adult periodontitis with no systemic disorder. All gingival tissues were obtained from sites with periodontal probing depth (PD) ≥4 mm and bleeding on probing (BOP) in periodontal surgery during periodontal treatment, and immediately frozen and stored at −80°C. Informed consent was obtained from each subject. The protocol was reviewed by the ethics committee of Kyushu Dental College.
Cell cultures. Normal human periodontal ligament fibroblasts (HPdLF; Cambrex, East Rutherford, NJ), neonatal normal human dermal fibroblasts (NHDF, Cambrex), and a human oral epithelial cell line (KB cells; ATCC, Manassas, VA, USA) derived from a human oral epidermoid carcinoma were used. The NHDF and HPdLF cells were cultured in stromal cell basal medium (SCBM, Cambrex) supplemented with 0.5 mL hFGF-B, 0.5 mL insulin, 25 mL fetal bovine serum (FBS), and 0.5 mL GA-1000 (Cambrex), under an atmosphere containing 5% CO 2 at 37°C. The KB cells were cultured as monolayers in Dulbecco's MEM (DMEM), supplemented with deemed to be statistically significant.
RESULTS
The concentrations of ET-1 and IL-1β in gingival tissues were determined using ELISAs. As illustrated by a scatter plot in Fig. 1 , the concentrations of IL-1β in gingival tissues were significantly correlated with those of ET-1 (Spearman's rank correlation analysis, r = 0.653; P = 0.001). The protein expression of ET A and ET B receptors in KB, NHDF, and HPdLF cells was confirmed by immunoblot analyses (Fig. 2) . In all cells, an immunoreactive band corresponding to ET A receptor protein was observed at 48 kDa. Furthermore, an immunoreactive band corresponding to ET B receptor protein was observed at 58 kDa in NHDF and HPdLF cells but not identified in KB cells. IL-1β mRNA expression in HPdLF and KB cells after stimulation by ET-1 at three concentrations
Reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was isolated from cells using ISOGEN reagent (Nippon Gene, Toyama, Japan). The cDNA was synthesized using the SUPERSCRIPT first-strand synthesis system (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocol. The integrity of the total RNA was verified by performing RT-PCR for the β-actin housekeeping gene. For RT-PCR, primers with the following sequences were used: sense, 5′-GGATATGGAGCAACAAGT GG-3′ and anti-sense, 5′-ATGTACCAGTTGGGG AACTG-3′ for human IL-1β (7), and sense, 5′-GT GGGGCGCCCCAGGCACCA-3′ and anti-sense, 5′-CTCCTTAATGTCACGCACGATTTC-3′ for β-actin (34) . The PCR products were subjected to electrophoresis in a 1.4% agarose gel, and DNA was visualized by ethidium bromide staining. The sizes of the IL-1β and β-actin PCR products were 263 bp and 546 bp, respectively. Band intensities were quantified using a Kodak photo documentation system (Eastman Kodak, Rochester, NY, USA).
Enzyme-linked immunosorbent assay (ELISA).
Tissue samples for ELISA were completely solubilized by grinding in phosphate-buffered saline (PBS). The concentration of ET-1 in gingival tissues was determined using a commercially available ELISA kit (R&D Systems, Minneapolis, MN, USA), following the manufacturer's protocol. The ELISA for measuring IL-1β in tissue homogenates was modified from the method of Cleary et al. (11) . Briefly, aliquots of either tissue homogenates or cytokine standards were added to the wells of 96-well microtiter plates. After incubation overnight at 4°C, the plates were incubated with anti-IL-1β monoclonal antibody (mAb; Hytest, Ltd., Turku, Finland). The amount of bound antibody was quantitated using HRP-conjugated anti-mouse IgG (Bio-Rad) and a TMB peroxidase EIA substrate kit (Bio-Rad). Furthermore, the ELISA for IL-1β in culture supernatants was performed using a commercial human ELISA kit (Endogen Inc., Cambridge, MA, USA), following the manufacturer's protocol.
Statistical analysis. Data are expressed as the mean ± standard deviation (SD) for triplicate determinations. The levels of IL-1β mRNA and protein were compared by ANOVA, with a post-hoc test. The correlations between the levels of ET-1 and IL-1β in the gingival tissues were evaluated using Spearman's rank correlation analysis. All statistical analyses were performed using SPSS 11.0 for Windows (SPSS, Chicago, IL, USA). A value of P < 0.05 was were determined by ELISA (Fig. 6A, 6B ). The levels of IL-1β released from HPdLF and KB cells were enhanced by stimulation with 100 nM ET-1 for 24 h, and this enhancement was inhibited by both BQ123 and BQ788. In KB cells, the ET-1-induced expression of IL-1β protein tended to be inhibited more strongly by BQ123 than by BQ788, although the difference was not statistically significant (Fig. 6B) .
DISCUSSION
To our knowledge, this is the first study to suggest an action of ET-1 in gingival tissue. We recently reported ET-1 expression and localization in the gingival tissues of periodontitis patients and first demonstrated that the expression of ET-1 protein was higher in inflamed gingival tissue than in non-inflamed tissue (33) . However, no previous studies have addressed the action of ET-1 in inflamed gingival tissue.
In the present study, we found a positive correlation between the concentrations of ET-1 and IL-1β proteins in gingival tissues. Moreover, we demonstrated that ET-1 could stimulate IL-1β mRNA expression and IL-1β protein release in HPdLF and KB cells in a dose-dependent manner. ET-1 has been previously reported to cause cytokine release in human primary astrocytes and bronchial epithelial cells (13, 23) ; however, little is known about ET-1-induced IL-1β expression in other cell types or its mechanism of action. Many studies have demonstrated that cytokines, including IL-1β, IL-2, IL-6, (1 nM, 10 nM, and 100 nM) for 12 h were assessed using RT-PCR (Fig. 3A, 3B) . In HPdLF and KB cells cultured in serum-starved medium, ET-1 tended to stimulate IL-1β mRNA expression in a dosedependent manner. Compared with the levels in cells without ET-1 treatment, the IL-1β mRNA levels were significantly higher in HPdLF cells treated with 10 nM and 100 nM ET-1 and in KB cells treated with 1 nM, 10 nM, and 100 nM ET-1. IL-1β protein expression in HPdLF and KB cells after stimulation with ET-1 at three concentrations (1 nM, 10 nM, and 100 nM) for 24 h was assessed by ELISA (Fig. 4A, 4B) . In HPdLF and KB cells cultured in serum-starved medium, ET-1 enhanced IL-1β protein expression in a dose-dependent manner. Compared with the levels in cells without ET-1 treatment, the IL-1β protein levels were significantly higher in the culture supernatants from HPdLF and KB cells treated with 1 nM, 10 nM, and 100 nM ET-1. The effects of ET-1 and its receptor antagonists on IL-1β mRNA expression in HPdLF and KB cells were determined using RT-PCR (Fig. 5A , 5B). IL-1β mRNA expression in HPdLF and KB cells was significantly enhanced by 100 nM ET-1 stimulation for 12 h. This enhancement was inhibited by both the ET A R and ET B R antagonists (BQ123 and BQ788, respectively), resulting in IL-1β mRNA levels that did not differ significantly from those of control cells without ET-1 or antagonist treatment. The effects of ET-1 and its receptor antagonists on the release of IL-1β from HPdLF and KB cells and TNF-α, can stimulate the production of ET-1 in various cell types (21, 24, 26, 36, 37) . In sinusitis of human nasal mucosa, it has been suggested that ET-1 and pro-inflammatory cytokines such as IL-1β may establish an inflammatory loop, via an autocrine or paracrine system, that could become independent of the original stimulus and contribute to long-term inflammatory changes of nasal mucosa (22) . Similarly, the correlation between ET-1 and IL-1β in gingival tissue may reflect an inflammatory loop related to the constant inflammatory condition of periodontitis. In one model of an inflammatory loop in periodontitis, ET-1 secreted by epithelial and endothelial cells of inflamed gingival tissues may act through an autocrine or paracrine pathway to induce IL-1β synthesis in epithelial cells and fibroblasts of the gingiva and promote IL-1β secretion by the cells. Additionally, the secreted IL-1β may simultaneously stimulate the expression of ET-1 in gingival tissues. IL-1β plays a central role in mediating a variety of inflammatory responses. Signal transduction by IL-1β occurs via the binding of IL-1β to its cognate receptors such as IL-1 receptors on target cells (9, 14) . Inhibition of IL-1β is an effective therapeutic strategy for several inflammatory disorders (20) . Human clinical trials have demonstrated the efficacy of IL-1 receptor antagonists in ameliorating inflammatory pain and bone resorption in patients with rheumatoid arthritis, an autoimmune and autoinflammatory disorder (19) . The potential downregulation of IL-1β signaling in the inflammatory process may be a useful treatment for controlling inflammatory responses in periodontitis. In the present study, we demonstrated that ET-1-stimulated upregulation of both IL-1β protein production and secretion by HPdLF and KB cells were inhibited by ET A and ET B receptor antagonists, which block the ET-1 signal to the cells. To date, there have been several reports on the inhibition of inflammatory development by ET receptor antagonists in various diseases (15, 16, 18, 28, 30) . Thus, the inhibition of ET-1 signaling to cells presents a potential therapeutic approach for controlling the IL-1β-dependent inflammatory response, and treatment with an ET A or ET B receptor antagonist may contribute to regulating the inflammation of gingival tissue. Studies are needed to develop these treatments for clinical application.
In conclusion, the results presented here suggest that ET-1 is involved in the regulation of IL-1β expression in gingival tissues, thereby inducing the inflammatory events of periodontitis. Further investigations of ET-1 and cytokines such as IL-1β will provide useful information for understanding the inflammatory process in periodontitis and for developing novel therapies to treat periodontitis. 
